ImmuCell Corporation: Upcoming Financial Results Announcement

Author: Evelyn Baker Updated: 02-20-2025 10:20 AM

ImmuCell Corporation Prepares for Financial Results Release

ImmuCell Corporation (NASDAQ: ICCC), an innovative company in the animal health sector, is gearing up to announce its unaudited financial results for the quarter and year ending December 31, 2024. This announcement is anticipated to be made after market closure on February 25, 2025. The financial updates are expected to showcase the company’s ongoing commitment to enhancing the health and productivity of dairy and beef cattle.

Conference Call Information

Following the release of the financial results, ImmuCell will host a conference call on the morning of February 26, 2025, at 9:00 AM ET. This call will provide investors and interested parties the opportunity to get insights directly from the company’s leadership regarding the recent results. To participate, attendees can dial (844) 855-9502 for toll-free access, or (412) 317-5499 for international calls. Additionally, a replay of the call will be available for a limited time after the event.

Financial Expectations and Annual Report

The company does not foresee any significant alterations to the preliminary sales results that were mentioned earlier in January for the fourth quarter of 2024. These figures will still reflect the growth trajectory that ImmuCell aims to maintain. Furthermore, the Annual Report on Form 10-K is slated for submission by March 31, 2025, which will provide a comprehensive view of the company’s performance throughout the year.

Corporate Insights and Product Background

ImmuCell is renowned for its commitment to developing products that cater to the specific needs of dairy and beef calves. The company’s flagship product, First Defense, is specifically designed to provide immediate immunity to newborn calves. Additionally, the company is in the process of developing Re-Tain, an innovative treatment option for dairy cows that addresses subclinical mastitis while eliminating the need for FDA-required milk discard or meat withholding labels. This positions ImmuCell as a frontrunner in providing alternatives to traditional antibiotics.

Company Profile and Future Outlook

As ImmuCell continues on its growth journey within the animal health industry, potential investors and stakeholders are encouraged to access the updated Corporate Presentation available through the Investors section of the ImmuCell website. This slide deck not only outlines the company’s mission but also articulates its strategies for future growth and expansion. The updated presentation will be accessible after the upcoming market close on February 25, 2025.

Contact Information

For further inquiries, stakeholders are encouraged to reach out to:

Corporate Contacts

Michael F. Brigham, President and CEO
ImmuCell Corporation
Phone: (207) 878-2770

Investor Relations

Joe Diaz, Robert Blum, and Joe Dorame
Lytham Partners, LLC
Phone: (602) 889-9700
Email: iccc@lythampartners.com

Frequently Asked Questions

What financial results will ImmuCell announce?

ImmuCell will announce its unaudited financial results for the quarter and year ending December 31, 2024.

When is the conference call scheduled?

The conference call is scheduled for February 26, 2025, at 9:00 AM ET.

How can I join the conference call?

Join the call by dialing (844) 855-9502 for toll free or (412) 317-5499 for international access.

What key products does ImmuCell offer?

ImmuCell is known for its First Defense product providing immediate immunity for calves and is developing Re-Tain for dairy cows.

How can I contact ImmuCell?

Contact Michael F. Brigham at (207) 878-2770 or email Lytham Partners for investor inquiries.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.